Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DSUT71
|
|||
| Drug Name |
JNJ-64251330
|
|||
| Synonyms |
Lorpucitinib; Lorpucitinib [INN]; OE1QTY7C25; UNII-OE1QTY7C25; 2230282-02-5; 1-(trans-4-(Cyanomethyl)cyclohexyl)-1,6-dihydro-N-(2-hydroxy-2-methylpropyl)imidazo(4,5-d)pyrrolo(2,3-b)pyridine-2-acetamide; Imidazo(4,5-d)pyrrolo(2,3-b)pyridine-2-acetamide, 1-(trans-4-(cyanomethyl)cyclohexyl)-1,6-dihydro-N-(2-hydroxy-2-methylpropyl)-; CHEMBL4473572; SCHEMBL20266878; SCHEMBL20266879; GTPL10631; BDBM387818; BDBM505107; US10294226, Compound Ex. 1; compound 2 [PMID: 32134643]; example 1 [WO2018112379A1]; JNJ64251330; JNJ-64251330; MS-27023; US11066406, Ex. 1; HY-109182; CS-0116453; 2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2-yl)-N-(2-hydroxy-2-methylpropyl)acetamide; 2-[3-[4-(cyanomethyl)cyclohexyl]-3,5,8,10-tetrazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,11-pentaen-4-yl]-N-(2-hydroxy-2-methylpropyl)acetamide; 2-{1-[trans-4-(cyanomethyl)cyclohexyl]-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2-yl}-N-(2-hydroxy-2-methylpropyl)acetamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 1 | [1] | |
| Company |
JOHNSON & JOHNSON
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H28N6O2
|
|||
| Canonical SMILES |
CC(C)(CNC(=O)CC1=NC2=CN=C3C(=C2N1C4CCC(CC4)CC#N)C=CN3)O
|
|||
| InChI |
InChI=1S/C22H28N6O2/c1-22(2,30)13-26-19(29)11-18-27-17-12-25-21-16(8-10-24-21)20(17)28(18)15-5-3-14(4-6-15)7-9-23/h8,10,12,14-15,30H,3-7,11,13H2,1-2H3,(H,24,25)(H,26,29)
|
|||
| InChIKey |
NJKMSBSVJSQUBU-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05014360) A Phase 1b Study to Evaluate the Efficacy and Safety of JNJ-64251330, a Janus Kinase (JAK) Inhibitor, in Participants With Familial Adenomatous Polyposis. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.